Novartis voltaren

Novartis has penned a $2 billion deal for a biotech whose next-gen anti-immunoglobulin E (IgE) program could offer a worthy successor to Xolair. Excellergy has been snapped up by the Swiss pharma only five months after emerging with $70 million in funds. Novartis has netted a pair of regulatory wins, winning European approval for an oral therapy in chronic spontaneous urticaria (CSU) and, separately, receiving World Health Organization (WHO) prequalification for its antimalarial medication. Anonymous discussion boards for medical equipment/device companies Biopharma news today spans M&A, clinical wins and regulatory milestones, as companies push forward in gene therapy, obesity and chronic disease treatments. Novartis pens $2B deal for allergy biotech with potential Xolair successorNovartis boardEisai, Alzheon drill down on promising results in high-risk Alzheimer’s subsetEisai board Amid an outpouring of pharma investment dollars into China, Novartis is the latest multinational drugmaker lining up to bolster its research and production operations in the country. The Swiss pharma will collectively invest more than 3.3 billion Chinese yuan (roughly $480 million) to soup up. Anonymous board for Novartis. Novartis shares slip, Avidity soars after $12 billion biotech dealNovartis boardInnovent, Lilly's mazdutide trumps Novo's semaglutide in head-to-head diabetes, weight loss studyEli Lilly board, Novo Nordisk boardMapLight goes public via $250M IPO to fund Cobenfy competitor The deal cycle is heating up, with pharma gearing up for a big M&A year, while earnings, IPOs and regulatory shifts fill out the rest. Big Pharma M&A set for mega year as patent expiries drive deal urgency Pharma/Biotech General Discussion board Moderna tops revenue estimates on stronger international COVID vaccine sales Moderna board Repatha sales help Amgen overcome Prolia biosimilar hits in. Novartis is making further workforce reductions at its U.S. headquarters in New Jersey, planning to remove 114 positions as the drugmaker rejigs its sales team for rare disease medicines. The Swiss pharma telegraphed the layoffs in a recent Worker Adjustment and Retraining Notification (WARN). Roche, Novartis underline U.S. plans after Trump pharma tariff announcementRoche board, Novartis boardAstraZeneca joins the DTC platform pack, offering up to 70% discounts on Farxiga, AirsupraAstraZeneca boardBiogen officially ends all AAV gene therapy work, prompting team restructure.

Meta: